Oxford Drug Design
Oxford Drug Design Ltd is a biotechnology company specializing in rapid and robust drug discovery powered by AI. They leverage their expertise in tRNA synthetase enzyme targeting and AI/Machine Learning to develop innovative therapeutics for cancer and other major diseases. Their unique combination of scientific knowledge and computational capabilities allows them to advance multiple drug candidates to the clinic efficiently. With a focus on oncology, they are positioned to make significant contributions to the pharmaceutical industry, supported by various funding initiatives and collaborations.
Oxford Drug Design
Oxford Drug Design Ltd is a biotechnology company specializing in rapid and robust drug discovery powered by AI. They leverage their expertise in tRNA synthetase enzyme targeting and AI/Machine Learning to develop innovative therapeutics for cancer and other major diseases. Their unique combination of scientific knowledge and computational capabilities allows them to advance multiple drug candidates to the clinic efficiently. With a focus on oncology, they are positioned to make significant contributions to the pharmaceutical industry, supported by various funding initiatives and collaborations.
TL;DR
Founded: 2001 (spin-out from University of Oxford Chemistry Department)
Headquarters / Base: Oxford, UK (Oxford Centre for Innovation)
Tech / Focus: AI-driven computational drug discovery; aminoacyl-tRNA synthetase (aaRS) expertise
Therapeutic areas: Oncology (first-in-class programmes) and anti-infectives/AMR
Reported funding to date: Over $12M (combined grants and equity)
Company Overview
Problem Domain
Rapid, AI-enabled discovery of novel therapeutics for cancer and antimicrobial-resistant infections.
Founded
2001
Industry
Biotechnology
Funding Track Record
Reported grant round recorded Feb 20, 2025
Convertible note recorded May 19, 2022
2019 rounds and grant-supported funding to advance AMR projects
Multiple earlier grants including support from CARB-X and the UK Department of Health and Social Care (DHSC/SBRI)
Investor Signal
“Mix of public/non-dilutive AMR funders (CARB-X, DHSC/SBRI, PACE-AMR) and venture/angel investors (Angel CoFund/ACF Investors, o2h Ventures, R42 Group, others)”